Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028531 | 0.81 | LTA4H (0.34) | MEN1KMT2A | |
| SCHEMBL20028911 | 0.80 | BRD4 (0.32) | MEN1KMT2A | |
| SCHEMBL20028849 | 0.79 | BRD4 (0.33) | KMT2A | |
| SCHEMBL20028321 | 0.78 | KMT2A (0.38) | MEN1KMT2A | |
| SCHEMBL20028848 | 0.73 | NPSR1 (0.32) | MEN1KMT2A | |
| SCHEMBL20022798 | 0.64 | GRIN2B (0.33) | — | |
| SCHEMBL18209875 | 0.61 | LTA4H (0.32) | — | |
| SCHEMBL19046617 | 0.60 | KMT2A (0.44) | MEN1KMT2A | |
| SCHEMBL20028324 | 0.57 | SMO (0.37) | KMT2A | |
| SCHEMBL1115558 | 0.57 | OPRD1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2019-01-22 | — | — | US | disclosed |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | MUTABILIS (FR) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183943-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | NQO1, PEPD, LCT | MEN1 1734/4885KMT2A 2940/4885 |
| US-20180093985-A1 | Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections | NQO1, PEPD, LCT | MEN1 1734/4885KMT2A 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.